FEMY (Femasys) Cash, Cash Equivalents, Marketable Securities : $7.61 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Femasys Cash, Cash Equivalents, Marketable Securities?

Femasys's quarterly cash, cash equivalents, marketable securities declined from Mar. 2024 ($17.84 Mil) to Jun. 2024 ($13.53 Mil) but then stayed the same from Jun. 2024 ($13.53 Mil) to Sep. 2024 ($7.61 Mil).

Femasys's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($24.78 Mil) to Dec. 2022 ($12.96 Mil) but then increased from Dec. 2022 ($12.96 Mil) to Dec. 2023 ($21.72 Mil).

Femasys Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Femasys's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Femasys Cash, Cash Equivalents, Marketable Securities Chart

Femasys Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

7.41

3.32

24.78

12.96

21.72

Femasys Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															8.69	21.72	17.84	13.53	7.61

Femasys Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Femasys (NAS:FEMY) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Femasys Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Femasys's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Femasys Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Femasys Inc (NAS:FEMY) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024

Website

https://www.femasys.com

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.

Executives

Keith J Kendall	director	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alistair Milnes	director	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Christine E Thomas	officer: SVP, Regulatory & Clinical	2836 SW 117TH STREET, GAINESVILLE FL 32606
Dov Elefant	officer: Chief Financial Officer	EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Wendy Perrow	director	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Edward Evantash	officer: Chief Medical Officer	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
John Dyett	director, 10 percent owner	11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025
Adams John Q Jr	director	35 WYCK HILL LANE, WESTLAKE TX 76262
Edward R Uzialko	director, 10 percent owner	4605 DUDLEY LANE, ATLANTA GA 30327
Charles Larsen	director	28 SANDPIPER ROAD, TAMPA FL 33609
Kathy Lee-sepsick	director, officer: Chief Executive Officer	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Daniel Scott Currie	officer: Senior VP, Operations	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Kelley Hoskin Violet Alexandria	officer: VP, Clinical & Medical Affairs	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Gary Thompson	director	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
William Benson Witte	director	11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025